(Q33370887)

26 July 2017

title

Phase II study of irinotecan combined with carboplatin in previously untreated small-cell lung cancer (English)

1 reference

26 July 2017

1 reference

1 reference

A Kinoshita

1

1 reference

26 July 2017

M Fukuda

2

1 reference

26 July 2017

H Soda

3

1 reference

26 July 2017

S Nagashima

4

1 reference

26 July 2017

M Fukuda

5

1 reference

26 July 2017

H Takatani

6

1 reference

26 July 2017

M Kuba

7

1 reference

26 July 2017

Y Nakamura

8

1 reference

26 July 2017

J Tsurutani

9

1 reference

26 July 2017

S Kohno

10

1 reference

26 July 2017

M Oka

11

1 reference

26 July 2017

Nagasaki Thoracic Oncology Group (NTOG)

12

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 May 2006

1 reference

British Journal of Cancer

26 July 2017

published in

1 reference

26 July 2017

volume

94

1 reference

26 July 2017

issue

9

1 reference

26 July 2017

page(s)

1267-1271

1 reference

Phase II study of irinotecan combined with carboplatin in previously untreated non-small-cell lung cancer.

26 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361403

Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361403

Phase I/II trial of gemcitabine plus cisplatin and etoposide in patients with small-cell lung cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361403

21 June 2018

Small cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361403

Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361403

Etoposide, ifosfamide and cisplatin (VIP) plus concurrent radiation therapy for previously untreated limited small cell lung cancer (SCLC): a Hoosier Oncology Group (HOG) phase II study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361403

Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361403

Phase I study of irinotecan combined with carboplatin in previously untreated solid cancers

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361403

Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361403

Dose-finding study of irinotecan and cisplatin plus concurrent radiotherapy for unresectable stage III non-small-cell lung cancer [seecomments].

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361403

Carboplatin versus cisplatin in solid tumors: an analysis of the literature

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361403

Clinical pharmacokinetics and dose optimisation of carboplatin.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361403

Irinotecan (CPT-11): pharmacology and clinical applications

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361403

Preclinical antitumor and toxicologic profile of carboplatin

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361403

Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum(II) analogue diamminecyclobutanedicarboxylatoplatinum

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361403

How large should a phase II trial of a new drug be?

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361403

Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361403

Carboplatin dosage: prospective evaluation of a simple formula based on renal function

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361403

Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361403

Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361403

Phase II trial of cisplatin/etoposide and concurrent radiotherapy followed by paclitaxel/carboplatin consolidation for limited small-cell lung cancer: Southwest Oncology Group 9713.

21 June 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6603079

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6603079

Regional lymph node classification for lung cancer staging

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6603079

Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6603079

Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6603079

Phase I study of irinotecan and cisplatin with concurrent split-course radiotherapy in unresectable and locally advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6603079

Phase I study of irinotecan and cisplatin with concurrent split-course radiotherapy in limited-disease small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6603079

Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6603079

Phase I/II study of altered schedule of cisplatin and etoposide administration and concurrent accelerated hyperfractionated thoracic radiotherapy for limited-stage small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6603079

Effects of carboplatin in combination with other anticancer agents on human leukemia cell lines

21 January 2018

1 reference

12 December 2020

Prediction of carboplatin clearance from standard morphological and biological patient characteristics

1 reference

12 December 2020

Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells

1 reference

12 December 2020

Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6603079

1 reference

Dimensions Publication ID

26 July 2017

1043397645

0 references

Fatcat ID

release_pkeuasqaszblnalfk5yi5y2h4y

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/pkeuasqaszblnalfk5yi5y2h4y

24 November 2022

mapped directly with Wikidata item

PMC publication ID

2361403

1 reference

26 July 2017

1 reference